Holen Sie sich die Stockscreener-App
10.72
3.77%
-0.42
Vorhandelsmarkt:
10.42
-0.30
-2.80%
Schlusskurs vom Vortag:
$11.14
Offen:
$11.14
24-Stunden-Volumen:
626.11K
Relative Volume:
0.87
Marktkapitalisierung:
$669.54M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-69.71M
KGV:
-8.982
EPS:
-1.1935
Netto-Cashflow:
$-54.12M
1W Leistung:
+1.61%
1M Leistung:
-25.40%
6M Leistung:
+11.43%
1J Leistung:
+177.00%
1-Tages-Spanne:
$10.45
$11.24
1-Wochen-Bereich:
$10.31
$11.36
52-Wochen-Spanne:
$3.33
$17.25
Design Therapeutics Inc Stock (DSGN) Company Profile
Firmenname
Design Therapeutics Inc
Sektor
Branche
Telefon
858-293-4900
Adresse
6005 HIDDEN VALLEY ROAD, CARLSBAD
Compare DSGN vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DSGN
Design Therapeutics Inc
|
10.72 | 695.77M | 0 | -69.71M | -54.12M | -1.1935 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Design Therapeutics Inc Stock (DSGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-16 | Eingeleitet | Jefferies | Buy |
| 2026-01-07 | Eingeleitet | Oppenheimer | Outperform |
| 2025-12-03 | Eingeleitet | Craig Hallum | Buy |
| 2025-12-03 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-11-20 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-05-07 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-11-14 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-08-15 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-15 | Herabstufung | SVB Securities | Outperform → Market Perform |
| 2023-08-15 | Herabstufung | Wedbush | Outperform → Neutral |
| 2023-05-04 | Hochstufung | Goldman | Sell → Neutral |
| 2022-06-10 | Eingeleitet | Wedbush | Outperform |
| 2022-05-02 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-01-19 | Eingeleitet | Goldman | Sell |
| 2021-04-20 | Eingeleitet | Goldman | Neutral |
| 2021-04-20 | Eingeleitet | Piper Sandler | Overweight |
| 2021-04-20 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Design Therapeutics Inc Aktie (DSGN) Neueste Nachrichten
Design Therapeutics (DSGN) Gains 2.28% – Approaching Key Resistance at $11.78Weekly Profile - newsline.com
DSGN Q1 2026 Earnings: EPS Beat as Net Loss NarrowsEarnings Expansion Phase - newsline.com
Design Therapeutics Stockholders Approve Director and Auditor at Meeting - TipRanks
Design Therapeutics (DSGN) grants George Simeon 30,000 stock options at $10.55 - Stock Titan
[Form 4] Design Therapeutics, Inc. Insider Trading Activity - Stock Titan
Design Therapeutics (DSGN) director awarded 30,000 options at $10.55 strike - Stock Titan
Director at Design Therapeutics (DSGN) awarded options on 30,000 shares - Stock Titan
Design Therapeutics (DSGN) grants director David Shapiro 30,000 options - Stock Titan
Director at Design Therapeutics (DSGN) awarded 30,000 stock options - Stock Titan
Design Therapeutics (NASDAQ: DSGN) details outcomes of 2026 shareholder meeting votes - Stock Titan
Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components - PR Newswire
DSGN Q1 2026 Earnings: Narrower-than-expected loss highlights cost disciplineSubscription Growth Report - newsline.com
Point72-affiliated holders report 5.1% stake in Design Therapeutics (DSGN) - Stock Titan
Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year? - Yahoo Finance
DESIGN THERAPEUTICS INC (DSGN) Stock Chart - ChartMill
DSGN: Early clinical data in Friedreich's ataxia support rapid advancement to registrational studies - TradingView
Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics - Business Wire
Design Therapeutics Drops Ahead of Jefferies, Trial Remains in Focus for DSGN - Bez Kabli
Waypoint Bio Raises $20M Series A Led by Amplify Partners to Advance AI-Designed Cell Therapies Toward the Clinic - Business Wire
Design Therapeutics (DSGN) Slides 2.42% as Biotech Stock Tests Key SupportButterfly Setup - The Legal Advocate
Design Therapeutics (DSGN) Dips as Key Support Holds After 2.42% DeclineNaked POC - The Legal Advocate
Design Therapeutics shares jump on encouraging Friedreich ataxia trial results (DSGN) - MSN
Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference - The Manila Times
Biotech Design Therapeutics to join Jefferies 2026 healthcare fireside chat - Stock Titan
Piper Sandler Reaffirms Their Buy Rating on Design Therapeutics (DSGN) - The Globe and Mail
Piper Sandler Maintains Design Therapeutics(DSGN.US) With Buy Rating, Maintains Target Price $20 - Moomoo
DSGN Q1 2026 Earnings: Narrower-Than-Expected Loss as Cost Discipline ContinuesPeak Earnings Alert - newsline.com
Design Therapeutics(DSGN) Stock Options Chain | Quotes & News - Moomoo
Design Therapeutics (DSGN) Consolidates Near Support After Marginal DeclineMonthly Profile - The Legal Advocate
Design Therapeutics (DSGN) Holds Steady Near Support as Consolidation PersistsVerified Analyst Reports - Newser
Design Therapeutics Inc. (DSGN) Q1 2026 Earnings: Narrower Loss Surpasses Expectations Amid Quiet QuarterGuidance Accuracy Score - Newser
Design Therapeutics (DSGN) price target increased by 17.05% to 17.51 - MSN
Design Therapeutics (DSGN) Edges Higher as Support Holds Above $10.60Social Trading Insights - Newser
Design Therapeutics Inc. (DSGN) Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Progress in Gene Therapy PipelineRevenue Inflection Point - Newser
Analysts Conflicted on These Healthcare Names: Design Therapeutics (DSGN), Pro Medicus Limited (OtherPMCUF) and Boston Scientific (BSX) - The Globe and Mail
BlossomHill Therapeutics Expands Board of Directors with the Appointments of Sheila Gujrathi, M.D., and John Schmid - The Manila Times
DT-216P2 Shows Dose-Dependent Frataxin Increases and Clinical Improvements After 4 Weeks of IV Dosing in Friedreich Ataxia - Neurology Live
RBC Capital Maintains Design Therapeutics(DSGN.US) With Buy Rating, Raises Target Price to $20 - Moomoo
Craig-Hallum Maintains Design Therapeutics(DSGN.US) With Buy Rating, Raises Target Price to $22 - Moomoo
Design Therapeutics stock wobbles after rare genetic disease data - MSN
Design Therapeutics, Inc. (DSGN) Discusses Data from RESTORE-FA Trial of DT-216P2 for Friedreich AtaxiaSlideshow (NASDAQ:DSGN) 2026-05-19 - Seeking Alpha
Nasdaq Down 200 Points; Brady Earnings Top Views - Sahm
Crude Oil Gains Over 2%; US Homebuilder Sentiment Increases In May - Sahm
Design Therapeutics (DSGN) Stock Forum and Discussion - Moomoo
Design Therapeutics Stock Wobbles After Rare Genetic Disease Data - Sahm
Design Therapeutics, Inc. Stock 12‑Month Price Target Raised to $20, Implies 39% Upside - TradingView
Design Therapeutics Down Over 25%, on Track for Largest Percent Decrease Since August 2023 -- Data Talk - Moomoo
RBC Capital raises Design Therapeutics price target on trial data By Investing.com - Investing.com Australia
Design Therapeutics Announces Biomarker and Clinical Data from Ongoing Phase 1/2 RESTORE-FA Trial of DT-216P2 in Friedreich Ataxia Patients - Minichart
Design Therapeutics reports positive trial data for FA treatment - Investing.com UK
Design Therapeutics reports positive trial data for FA treatment By Investing.com - Investing.com Australia
Finanzdaten der Design Therapeutics Inc-Aktie (DSGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):